These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 21305118)

  • 1. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
    Brewer GJ
    Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The onset of psychiatric disorders and Wilson's disease].
    Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
    Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
    Hoogenraad TU
    Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
    Brewer GJ
    Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
    Brewer GJ; Merajver SD
    Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogenesis and treatment of Wilson's disease].
    Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
    Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risks of free copper in the body and the development of useful anticopper drugs.
    Brewer GJ
    Curr Opin Clin Nutr Metab Care; 2008 Nov; 11(6):727-32. PubMed ID: 18827576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Wilson's disease].
    Kovacević I; Zekan M
    Acta Med Croatica; 2003; 57(3):227-35. PubMed ID: 14582469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticopper efficacy of captopril and sodium dimercaptosulphonate in patients with Wilson's disease.
    Wang XP; Yang RM; Ren MS; Sun BM
    Funct Neurol; 2003; 18(3):149-53. PubMed ID: 14703896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
    Brewer GJ
    Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.
    Weiss KH; Askari FK; Czlonkowska A; Ferenci P; Bronstein JM; Bega D; Ala A; Nicholl D; Flint S; Olsson L; Plitz T; Bjartmar C; Schilsky ML
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):869-876. PubMed ID: 28988934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
    Esmaeli B; Burnstine MA; Martonyi CL; Sugar A; Johnson V; Brewer GJ
    Cornea; 1996 Nov; 15(6):582-8. PubMed ID: 8899270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical considerations for an effective medical therapy in Wilson's disease.
    Weiss KH; Stremmel W
    Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Wilson's disease with zinc. XIII: Therapy with zinc in presymptomatic patients from the time of diagnosis.
    Brewer GJ; Dick RD; Yuzbasiyan-Gurkan V; Johnson V; Wang Y
    J Lab Clin Med; 1994 Jun; 123(6):849-58. PubMed ID: 8201263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.
    Brewer GJ
    Exp Biol Med (Maywood); 2001 Jul; 226(7):665-73. PubMed ID: 11444102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Wilson's disease with zinc. VI. Initial treatment studies.
    Brewer GJ; Yuzbasiyan-Gurkan V; Lee DY; Appelman H
    J Lab Clin Med; 1989 Dec; 114(6):633-8. PubMed ID: 2592853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy.
    Brewer GJ; Johnson VD; Dick RD; Hedera P; Fink JK; Kluin KJ
    Hepatology; 2000 Feb; 31(2):364-70. PubMed ID: 10655259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.